Recently, nasal glucagon (NG; Eli Lilly and Company, Indianapolis, Indiana) has been undergoing development as a rescue treatment for SHE. [15] [16] [17] [18] Development of NG was informed by research dating back to the 1980s, in which the potential of intranasal glucagon to raise blood glucose levels was investigated in populations with and without diabetes. [19] [20] [21] The novel NG is a single-use, portable, ready-to-use device containing 3 mg of dry glucagon powder. In a clinical trial of adults with type 1 diabetes (T1D), NG showed efficacy similar to intramuscular glucagon (1 mg). 17 In real-world studies, NG was an effective treatment for SHEs in adult patients with T1D, and no additional emergency health services were required for patients to return to normal status. 15 Importantly, a simulation study demonstrated much better usability for NG relative to IG. 12 Administration of full glucagon doses and therefore successful treatment were more likely when using NG.
The aim of the present analysis was to evaluate the economic impact of NG's usability advantage over IG in the US setting. Across the SHE treatment pathway, costs were compared between treatments to assess the per-event costs and budget impact of introducing NG to the US market.
Methods

Analytic Framework
A de novo model was developed in Microsoft Excel to evaluate the economic impact of NG. The model combined a costoffset component (a type of cost-minimization analysis [CMA] ) and a budget impact component (Figure 1 ).
In the cost-offset component, NG and IG were compared per SHE for which a user, either a caregiver (of a person with diabetes) or an acquaintance (willing to help a patient with SHE), attempted treatment with either glucagon, conditional on the SHE having already occurred. Mean per-SHE treatment costs over the entire treatment pathway ( Figure 2 ) were compared for treatment attempts with NG and IG. This comparison provided an "instantaneous," per-event perspective on how the usability advantage of NG affected SHE-related treatment costs. Cost-offset results depended on treatment outcome probabilities and costs but not on diabetes type (which did not affect treatment success probabilities), SHE incidence (as the SHE was assumed to have occurred already), mortality, or market share (which affected the population-level number of owners of a certain type of glucagon but not treatment success).
The budget impact component assessed the populationlevel impact of introducing NG to the market, by combining cost-offset results with population-specific SHE incidence and mortality data as well as market share projections. The analysis also accounted for costs incurred by individuals without glucagon and cases where treatment with glucagon was not attempted. Budget impact was assessed comparing a scenario with the current intervention mix (patients had no kit or an IG kit) with a scenario in which NG was available (so patients had no kit, an IG kit or NG). This analysis extended the per-event cost-offset perspective to patient populations, to assess the magnitude of overall changes in SHErelated spending.
Differences between treatments in the time to onset of action and administration time were not considered in the analysis as no evidence was available to suggest their impact on cost outcomes. In addition, all adverse events in clinical trials were of mild or moderate severity, which were considered unlikely to be associated with resource utilization and therefore not included in the analysis. 18 
SHE Treatment Pathway
The model was centered on a representation of the emergency treatment pathway for SHE (Figure 2 ). This pathway, which covers treatment decisions and outcomes, was developed based on reviews of the published literature, market research, treatment guidelines and emergency care pathways.
3,22-25 Each decision and outcome was associated with a probability of occurrence and a cost. Mean treatment costs were calculated as expected costs per SHE over the entire pathway.
Inpatient stays were not considered in the treatment pathway. In inpatient stays following SHE, patients are usually admitted not solely for SHE but for other acute and/or chronic comorbidities. 26 Glucagon was not expected to affect these comorbidity-related inpatient stays and their associated costs so they were excluded from the analysis.
Analysis Settings
The analysis was conducted from the perspective of a US insurer similar to a Medicare Advantage Plan. The time horizon in the cost-offset component was instantaneous while a 2-year time horizon was used in the budget impact analysis, taking into account one glucagon lifecycle based on the 2-year shelf life of IG. Populations considered in the budget impact component were patients with insulin-treated diabetes, who were considered to be at increased hypoglycemia risk. 3 Specifically, patients with T1D and type 2 diabetes treated with basal-bolus insulin (T2D-BB) were included. In the budget impact analysis, 10 000 patients were modeled for each population and scenario.
Input Data
Treatment Pathway Probabilities. Probabilities in the treatment pathway were derived from published sources wherever possible and equal for NG and IG, with the exception of treatment success (Table 1) . While 94% of caregivers and 93% of acquaintances delivered a full glucagon dose if using NG, only 13% and 0%, respectively, did when using IG.
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Costs. Costs were considered for decisions and outcomes in the treatment pathway. Costs associated with treatment were assumed to match fees published by the Centers for Medicare and Medicaid Services, supplemented from the literature where necessary (Table 2) . [27] [28] [29] Costs were expressed as 2017 US dollars ($). 30 Costs projected by the model were distinguished into acquisition costs for glucagon and treatment costs associated with professional medical help.
SHE Incidence and Mortality. SHE incidence and background mortality were included in the budget impact component. For patients with T1D, an incidence rate of 366 SHEs per 1000 person-years (PY) was obtained from the conventional treatment arm of the Epidemiology of Diabetes Interventions and Complications (EDIC) cohort. 2 For patients with T2D-BB, an incidence rate of 80 SHEs per 1000 PYs was assumed based on a systematic review. 31 Background mortality was sourced from Diabetes Control and Complication Trial/ EDIC data for patients with T1D (2.63 deaths per 1000 PYs) and a 5-year study of US patients with diabetes for patients with T2D-BB (32.3 deaths per 1000 PYs).
32,33
Market Share. For the comparison of current and new intervention mix scenarios, glucagon ownership rates were projected. In both populations, a constant 40% of patients were assumed not to own any glucagon. 34 Of patients owning glucagon, 80% were projected to own an IG kit in the first year after NG entered the market, compared with 70%, 60%, and 55% in years 2-4 and 50% from year 5 onward in both populations. For simplification, patients were assumed to own only one kit at any given time so glucagon acquisition costs were incurred once per 2-year glucagon lifecycle, unless glucagon was used and subsequently replaced. After either use or expiration, glucagon was assumed to be replaced with the same type of glucagon.
Uncertainty Analysis
A range of sensitivity analyses was conducted to investigate the impact of assumptions on and identify key drivers of results.
The influence of treatment success probabilities was explored using lower and upper 95% confidence interval bounds for proportions successfully administering at least partial glucagon doses. Lower (upper) bounds for caregivers were 24% (78%) when using IG and 81% (100%) when using NG. The corresponding values for acquaintances were 0% (42%) for IG and 79% (100%) for NG, respectively. In addition, a scenario was explored where EMS call-out was mandatory so all caregivers and acquaintances called out EMS regardless of treatment success with glucagon.
For sensitivity analyses of budget impact, the proportion of users not attempting treatment was increased up to 75%. Glucagon acquisition costs were varied by ±20% and alternative cost estimates for emergency department (ED) visits were used. 29, 35 The impact of SHE incidence was explored by running the model with alternative rates from the literature. 1, 31, 36 Budget impact was also evaluated over different time horizons (1-6 years) and for alternative market shares (±10% versus base case projections for IG).
Results
Base Case Results
Cost-offset analysis showed that using NG was associated with reduced per-event costs compared with using IG. Modeled mean costs per SHE for which treatment was attempted using glucagon were $1345 if an IG kit was used and $354 if NG was used, yielding a cost-offset of $992 with NG. As IG and NG acquisition costs were equal, the costoffset resulted entirely from EMS transports and ED treatment avoided as professional medical help was less likely to be required given the usability advantage of NG (Table 3) .
At the population level, for 10 000 modeled patients with T1D, projected total SHE-related costs over 2 years were $10.84 million for the current intervention mix. The corresponding cost for the new intervention mix was projected at $9.76 million, leading to an estimated cost reduction of approximately $1.09 million over 2 years following the introduction of NG.
For 10 000 modeled patients with T2D-BB, the projected total SHE-related costs were $3.62 million and $3.39 million with the current and new intervention mix, respectively. Introduction of NG was estimated to reduce SHE-related treatment costs by approximately $230 000 over 2 years in this patient group.
In both populations and analyses, acquisition costs of IG and NG were equal so the entire reduction in SHE-related spending was due to reduced spending on EMS transports and ED treatment.
Sensitivity Analyses
The cost-offset and reductions in total SHE-related spending associated with NG were confirmed in sensitivity analyses. In one-way sensitivity analyses, NG was consistently associated with cost-offset and reduced overall spending versus IG. ED treatment costs were identified as key drivers of results ( Figure 3) . With regard to glucagon costs, even when increasing NG costs by 20% (or, equivalently, decreasing IG kit costs by 20%), NG was still associated with cost-offset and reduced SHE-related treatment spending relative to IG. Relative to the base case, changes in input values and assumptions that reduced the costs or increased the use of professional medical help favored IG. In these cases, the usability advantage of NG translated into smaller cost reductions.
In the budget impact analysis, SHE rates and time horizon were identified as key drivers of results ( Figures S1 and S2 ). For the new intervention mix, higher SHE rates and longer time horizons were associated with larger reductions in spending for NG relative to IG.
In two-way sensitivity analyses, cost-offsets and reduced expenditure were also observed for NG relative to IG (Table  S1 ). When assuming higher success probabilities for IG and lower probabilities for NG relative to the base case, costoffset and budget impact were reduced but still indicated reduced spending associated with NG. NG was also associated with cost-offset and reduced spending if EMS call-out was mandatory although reductions were smaller than in the base case. In this scenario, patients who had returned to normal by the time EMS arrived due to successful prior treatment with glucagon were assumed to be more likely released on the scene than patients in whom glucagon treatment had failed. When lower IG acquisition costs were combined with higher NG acquisition costs, the new intervention mix increased glucagon costs but still reduced professional medical treatment costs, leading to a cost-offset with NG relative to IG and a decrease in overall SHE-related expenditure relative to the current intervention mix.
Discussion
This study provided evidence that, in the United States, the usability advantage of NG can reduce the costs of SHEs with treatment attempted by non-medically trained users using glucagon. In addition, reduced overall SHE-related spending was observed for populations with T1D and T2D-BB. Reduced spending resulted from less professional medical help required, namely avoidance of EMS transports and ED treatment.
Results from this analysis suggested that NG's usability advantage translated to lower SHE-related costs in patients with insulin-treated diabetes. For SHE prevention, novel approaches have been explored in recent years. 37, 38 Treatment for SHEs, however, has seen little progress despite the challenges associated with IG. 13, 34, 39 In the 1980s and 1990s, initial research was conducted on nasally administered glucagon formulations but none was brought to market. 21 NG was the first innovative glucagon formulation to undergo a clinical development program, which showed NG to have clinical efficacy similar to IG. 18 The de novo model was designed to be flexible and accommodate a range of different assumptions. For example, while a closed cohort of 10 000 patients owning at most one glucagon kit at any one time was used for clarity of presentation, this could easily be modified and explored in future analyses. However, the present analysis has potential shortcomings that should be acknowledged. First, due to a lack of studies investigating decision-making during SHE, published data were not available for all treatment decision and outcomes in the treatment pathway so simplifying assumptions had to be made. Extensive sensitivity analyses were performed, which consistently showed reduced per-event costs and overall SHE-related spending with NG. No further action following successful treatment with glucagon was assumed in budget impact base case analyses. This assumption was considered to reflect real-world practice as most SHEs take place outside the health care system, indicating that they are resolved without professional medical intervention. 40 While data on SHE occurring outside the health care system are still sparse, results from real-world studies of NG showed that no professional medical help was required for treating SHE. 15 In addition, sensitivity analyses showed that the impact of this assumption on budget impact results was comparatively small. Second, the study on which treatment success probabilities were based was small (n = 31). 12 The study sample was based on sample size calculations to achieve ≥95% power, assuming a within-subject mean difference of ≥40 seconds between glucagon formulations in the time required to deliver a dose (due to higher than expected drop-out in the acquaintance arm, statistical power for acquaintance analysis was 94%). 13 Overall, the study was well aligned with previous results regarding the poor usability of IG so bias, if any, was probably small. 13 In addition, while the study was a simulation and may not have captured the full emotional distress associated with SHE, it seems plausible that distress would more negatively affect administration of IG than of NG, given the complexity of administration. The difference between the two treatments obtained in the simulation might therefore underestimate the real-world usability advantage of NG.
Third, the cost perspective was not straightforward to define for the US setting. Medicare Part B covers nonhospital medical services but not drugs, while the opposite holds for Part D. 41 Medicare Advantage Plans cover both but are provided by a wide range of commercial payers, for which data on cost and fee structures are not generally available. To obtain a coherent set of costs for the present analysis, fees were sourced from published Medicare Part B schedules. 29 This choice was likely conservative from the perspective of commercial payers, which, for example, may also cover EMS transport with release at the scene. Results are therefore likely to provide a lower bound for the reduction in spending with NG relative to IG for these payers.
The present study used a cost-offset and budget impact analysis design, which was considered appropriate to model the economic impact of the usability advantage of NG. The costs and benefits considered were short-term, relating to the SHE and subsequent emergency treatment. No changes in long-term benefits or costs following improved hypoglycemia emergency treatment were assumed. Together with the "economic hypothesis of weak dominance"-that NG is as safe and effective as IG but less costly-the short-term focus justified the use of CMA. 17, 42 CMA is also appropriate if based on a noninferiority trial where the difference in cost was so large that plausible efficacy differences would not change conclusions. 42 This criterion was met as the underlying noninferiority trial showed pharmacodynamic responses to IG and NG to be very similar while differences in administration success probabilities were so large that any changes were unlikely to affect conclusions (as shown in sensitivity analyses). 12, 17 Current uptake and use of IG kits are poor given the complexity of IG administration, indicating that novel hypoglycemia treatments are urgently required. 11, 13, 14, 39, 43 Compared with the currently available IG, NG is associated with a usability advantage that translates into benefits to patients, due to a higher probability of treatment success, and to payers, due to reduced costs associated with professional medical help for SHE. Relative to IG, NG was considered to represent a more efficient use of health care payers' resources. In addition, NG may not only provide clinical and economic benefits but also reduce fear of hypoglycemia and improve better quality of life due to increased confidence in treatment and avoidance of ED visits while reducing costs by avoiding use of professional medical help.
8,44
Conclusions
As a novel treatment option for SHE, NG is easier to administer than IG and therefore has the potential to improve the probability of successful treatment for SHEs relative to IG. This usability advantage of NG was estimated to translate into reduced per-event costs and reduced overall SHE-related spending as SHEs are more likely to be resolved without professional medical help. 
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